Tomorrow Investor

Berkshire’s Lag Amid S&P 500 Surge Explored

A significant person from Berkshire Hathaway speaking at an event.
A significant person from Berkshire Hathaway speaking at an event.

Shares of Berkshire Hathaway (BRK.B) declined approximately 1% month-to-date as the S&P 500 rallied more than 9% to reach new record levels, demonstrating the conglomerate’s lag during periods of widespread market enthusiasm 1.

This performance gap illustrates how Berkshire’s value-oriented investment strategy may trail during periods of momentum-fueled market advances, creating potential pressure on the stock as capital flows toward growth-oriented investments.

Key Takeaways

  • Berkshire shares dropped 1% while S&P 500 gained 9%
  • Stock down 12% since Buffett’s CEO transition announcement
  • Market rally driven by easing Iran conflict concerns

Market Reaction & Context

The S&P 500 reached above 7,100 for the first time, representing one of the most rapid market reversals seen in at least 36 years 1. Relief regarding a possible resolution to U.S.-Iran tensions contributed to the widespread market advance.

In contrast, Berkshire’s Class A and B shares experienced month-to-date declines approaching 1%, with the stock finishing Friday trailing the benchmark index by 9.7 percentage points 1. This marks the company’s largest performance differential against the S&P 500 recorded so far in 2026.

Leadership Transition Impact

Berkshire’s stock has faced headwinds since reaching all-time highs on May 2, 2025, which preceded Warren Buffett’s announcement of his planned departure as CEO at year-end 1. Both share classes have declined over 12% since that announcement, though they remain approximately 3% above their early-August lows.

The pending leadership change to Greg Abel seems to be influencing investor confidence, as market participants evaluate whether new management can preserve Berkshire’s historic performance achievements.

Investment Strategy Divergence

One analyst observed that the performance disparity reflects Berkshire’s investment approach. “He’s not invested in speculative high-beta names. So Berkshire won’t keep up with short-term fluctuations. But it’s hard to overlook his long-term performance,” said Zach Scheidt from Paradigm Press 4.

The company’s emphasis on undervalued, stable enterprises typically results in underperformance during market exuberance while offering protection during downturns.

Financial Position Remains Strong

Notwithstanding the stock’s relative weakness, Berkshire retains a robust balance sheet featuring $373.3 billion in cash as of December 31 1. The conglomerate’s market value surpasses $1 trillion, positioning it among the globe’s most valuable corporations.

The company’s varied collection of wholly-owned enterprises and equity investments continues producing significant cash flow, maintaining flexibility for future investments and acquisitions.

Outlook

Although Berkshire confronts short-term challenges from the leadership change and its value-focused methodology, the company’s core advantages remain solid. The present underperformance could create an attractive entry point for long-term investors seeking exposure to a diversified, cash-abundant conglomerate.

Market observers will pay close attention to Berkshire’s upcoming annual shareholders meeting for guidance on the company’s strategic path under new leadership.

Not investment advice. For informational purposes only.

References

1Alex Crippen (April 18, 2026). “Berkshire shares left behind as S&P 500 rallies to record high”. CNBC. Retrieved April 19, 2026.

2CNBC (April 18, 2026). “Berkshire shares left behind as S&P 500 rallies to record high”. X (formerly Twitter). Retrieved April 19, 2026.

3Earl Cotten (April 18, 2026). “Berkshire Shares Left Behind: What to Do as the S&P 500 Rallies to a Record High”. Medium. Retrieved April 19, 2026.

4Zach Scheidt (April 18, 2026). LinkedIn comment on CNBC post. LinkedIn. Retrieved April 19, 2026.

Tomorrow Investor
The Tomorrow Investor

Markets research for retail investors

Independent coverage of small-cap equities, biotech catalysts, and emerging market opportunities.